Clinical Trial Update: Rituximab for Anti-cytokine Autoantibody-Associated Diseases [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating Rituximab for anti-cytokine autoantibody-associated diseases, including Pulmonary Alveolar Proteinosis and Severe Mucocutaneous Candidi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucocutaneous Candidiasis
• Pulmonary Alveolar Proteinosis

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Pulmonary Alveolar Proteinosis (PAP), Severe Mucocutaneous Candidiasis | Phase 1 | Status: COMPLETED